Mink Therapeutics, Inc. Stock Price, News & Analysis

MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on iNKT cell therapies for cancer and immune-mediated diseases, will announce its Q1 2022 financial results and business update on May 10, 2022, before market opens. The disclosure will be made via press release and available on the company's investor website. MiNK is advancing a pipeline of native and next-generation engineered iNKT therapies, aiming for scalable off-the-shelf delivery.

MiNK Therapeutics (NASDAQ: INKT) is advancing its allogeneic invariant natural killer T (iNKT) cell therapies, particularly AgenT-797, in ongoing clinical trials for solid tumors and COVID-19 related ARDS, showing a remarkable 75% survival rate in treated patients. No lymphodepletion or serious side effects such as cytokine release syndrome have been reported. The company completed a $46 million IPO and recorded a cash burn of approximately $13 million in 2021, with a cash balance of $39 million as of year-end. MiNK plans to manufacture over 10,000 doses of iNKT cells annually to support its clinical programs.

MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its fourth quarter and full year 2021 financial results and business update on March 18, 2022. The company specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The financial report will be accessible via a press release and the investor section of the company's website. MiNK's pipeline includes native and engineered iNKT programs aimed at scalable manufacturing and off-the-shelf delivery.

MiNK Therapeutics has initiated a Phase 1 clinical trial for AgenT-797, targeting patients with solid tumor cancers. The therapy can be dosed up to 1 billion cells without lymphodepletion, showing no signs of cytokine release syndrome or neurotoxicity. Clinical trials are also being conducted for multiple myeloma and viral ARDS. Preliminary results indicate a favorable safety profile and promising early clinical activity, especially when combined with approved anti-PD-1 checkpoint inhibitors. The company is focused on developing allogeneic iNKT cell therapies for cancer treatment.

MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27, 2022, at 12:00 PM ET. The event will discuss the company's advancements in iNKT cell therapies aimed at treating cancer and immune-mediated diseases. Investors can access the live presentation and a replay through MiNK's website after the event.

MiNK is focused on developing scalable iNKT cell therapies, enhancing treatment options in oncology.

MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat hosted by Evercore on December 1, 2021, at 8:25 AM ET. This event will focus on the company's innovative allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases. Interested parties can register for the event online, and a replay will be available afterward on the MiNK website.

For further details about MiNK Therapeutics and its clinical-stage developments, visit their official website.

MiNK Therapeutics announced preliminary survival data from its phase 1 study of agenT-797, an iNKT cell therapy for COVID-19 patients experiencing respiratory distress. The therapy achieved a 77% survival rate among older, ventilated patients, significantly higher than the national average of 20-30%. Additional findings showcased evidence of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma patients. The company plans to expand its clinical programs, including trials for solid tumors cleared by the FDA.

MiNK Therapeutics announced new data presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing the potential of its iNKT cell therapies, particularly agenT-797. The data emphasize anti-tumor activity, tissue distribution, and the engineered iNKT cells' capabilities against solid and liquid tumors. Presentations will cover three abstracts, detailing clinical persistence and preclinical efficacy. The full text of the abstracts will be available on November 9, ahead of the investor section release on November 12.

MiNK Therapeutics has successfully closed its initial public offering of 3,333,334 shares of common stock at a price of $12.00 per share, generating gross proceeds of approximately $40 million. The shares began trading on the Nasdaq Global Market under the ticker symbol INKT on October 15, 2021. The offering was managed by Evercore ISI and William Blair, with co-managers B. Riley and Baird. This funding will support the company’s efforts to develop its pioneering iNKT cell therapies for cancer and immune-mediated diseases.